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Abstract
Classifying Cancer Genomic Alterations Using Machine Learning and Multi-Omic
Data
by
David Haan
In 2018, an estimated 1,762,450 new cases of cancer will be diagnosed in the United States
and 606,880 people will die from these diseases. Cancer is a group of diseases characterized
by the overgrowth of abnormal cells as the result of genomic mutations. Mutations that initi-
ate tumorigenesis are called driver mutations whereas those which cannot are called passenger
mutations. Driver mutations define a tumor’s subtype and can be used as therapeutic targets
thus, deciphering driver mutations from passenger mutations is of utmost importance as we
strive to improve cancer treatment. As the cost of genome sequencing is decreasing, the amount
of available tumor data is increasing, making it possible to conduct large scale computational
analysis with machine learning to identify novel tumor characteristics. There have been nu-
merous recent collaborations to collect, sequence, and analyze human tumors. The largest of
these collaborations, the Cancer Genome Atlas (TCGA), is a comprehensive analysis of 9,000
patients and 33 sub types cataloging mutation data, DNA, mRNA, methylation, and protein
expression. Whereas the TCGA is mostly whole exome sequencing, the International Cancer
Genome Consortium (ICGC) has begun contributing data from the whole genome sequencing
of a few thousand tumors. Using both the TCGA and ICGC data, I performed four new variant
classification analyses using both unsupervised machine learning techniques and a novel su-
xvii
pervised machine learning technique to identify tumor subtypes, driver mutations and potential
therapeutic targets. I first present an analysis in which I used supervised machine learning to
determine the most important genomic features responsible for accurate gene fusion detection
among a set of fusion detection methods. Next, I present a method of unsupervised machine
learning in which I classify non-coding variants of splicing factors as potential driver mutations
in a number of tumor types. Third, I analyze telomere data from ICGC whole genome sequenc-
ing data using unsupervised machine learning to identify 4 subtypes of telomere maintenance
mechanisms(TMM) among 2,500 tumor samples. Lastly, I present a new variant classification
method called LURE, which uses supervised machine learning to classify variants based on
existing signatures from known driver mutations.
xviii
Chapter 1
Introduction
Approximately 39.3 percent of men and women will be diagnosed with cancer of any
site at some point during their lifetime[2]. In 2016, there were an estimated 15,338,988 people
living with cancer of any site in the United States[2].
Cancer is a genetic disease caused by mutation and selection in somatic cells. Mu-
tations in normal cells are usually repaired or result in apoptosis. Whereas in cancer cells mu-
tations accumulate, leading to uncontrolled growth and tumorigenesis. There are two broadly
defined types of mutations: drivers and passengers. Tumors contain around 2-5 driver mutations
that cause and accelerate cancer, and about 10-200 passenger mutations which are accidental
byproducts of thwarted DNA repair mechanisms[3]. Driver mutations define key characteris-
tics of the tumor and may offer therapeutic targets, yet identifying them amid the myriad of
passengers remains a challenge.
The Cancer Genome Atlas (TCGA) is a publicly accessible dataset of cancer samples
from the National Cancer Institute (NCI)[?]. TCGA catalogues mutations, mRNA, miRNA,
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DNA methylation, copy number variation, and protein expression data for roughly 11,000 pa-
tients across 33 cancer types[?]. The identification of driver mutations played a fundamental
role in many TCGA analyses. Whereas the TCGA is mostly whole exome sequencing, the In-
ternational Cancer Genome Consortium (ICGC) has begun contributing data from the whole
genome sequencing of a few thousand tumors. Using both the TCGA and ICGC data, I per-
formed four new variant classification analyses using both unsupervised machine learning tech-
niques and a novel supervised machine learning technique to identify tumor subtypes, driver
mutations and potential therapeutic targets.
There are two types of machine learning methods: supervised and unsupervised. Un-
supervised learning methods, such as hierarchical clustering and T-distributed Stochastic Neigh-
bor Embedding(t-SNE), are effective at visualizing high dimensional data and identifying clus-
ters or patterns in the data[4]. Supervised machine learning uses prior knowledge or labels to
divide data into two or more classes[4]. By training a classification model on prior knowledge,
supervised machine learning can make predictions about unknown or unlabeled data[4]. In this
thesis, I present unsupervised and supervised machine learning methods I performed on cancer
genomic data to classify mutations or variations found in the genomes of human tumors.
In chapter 3, I recapitulate my participation in a bioinformatics community challenge
ranking user-submitted gene fusion detection methods. In this challenge, we spiked gene fusion
transcripts into a few human cancer cell lines and asked participants to run their own gene
fusion detection methods on these datasets. I was tasked with performing analysis on the data
to determine if the presence of certain genomic features near a fusion prevented methods from
detecting the fusion. After collecting a set of genomic features for each fusion, I used a random
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forest, a supervised machine learning method, to predict the false positive and false negative
fusion events called by each method. I then preformed a feature importance analysis to identify
the genomic features responsible for each method’s incorrect fusion detection.
Next, I sought to classify mutation variants by developing a supervised machine learn-
ing tool called Learning UnRealized Events (LURE). LURE, discussed in chapter 4, associates
alterations between samples by finding similar signatures in feature data, such as mRNA ex-
pression data or methylation data. LURE achieves this by training a classifier on tumor sample
feature data of a known driver mutation (the bait), applying the classifier to find ”bait”-absent
samples with a high classifier score, and identifying other alterations (the ”catch”) in those sam-
ples that correlate with the high classifier score. Using LURE, I identify new associations across
pan-cancer data and find putative new driver alterations involved with MAPK signaling. In ad-
dition, I associate new driver alterations with the alternative lengthening of telomeres (ALT), a
telomere maintenance mechanism (TMM), in sarcomas.
In chapter 5, I discuss variant classification of non-coding mutations using supervised
learning. First, using hierarchical clustering of pathway expression data, I relate non-coding
mutations of splicing factors with coding mutations of the same splicing factors. Next, using
t-SNE on telomere related features, I identify 4 unique groups of tumor samples that employ
different TMMs and associate mutations with each of these groups. In chapter 6, I outline
conclusions based on my research and discuss the future directions of cancer genomics.
3
Chapter 2
Background
2.1 Cancer is a Genetic Disease
Cancer is a genetic disease typically resulting from an accumulation of mutations[3].
Mutations in normal cells generally result in repair or cell suicide. However, in cancer cells, the
mutations accumulate leading to an uncontrolled growth otherwise known as a tumor. There are
two broadly defined types of mutations, driver and passenger mutations. Tumors contain around
2-5 driver mutations which cause and accelerate cancer, and about 10-200 passenger mutations
that are accidental byproducts of thwarted DNA repair mechanism. Driver mutations define a
tumor’s subtype and can be used as therapeutic targets.
2.2 The Cancer Genome Atlas
TCGA (cancergenome.nih.gov) is a publicly accessible collection of data from the
NCI[5]. This atlas of data is a comprehensive analysis of 9,000 patients and 33 cancer subtypes
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cataloging mutation data, DNA, mRNA, methylation, and protein expression[5]. The majority
of the TCGA data is whole exome sequencing that covers only protein coding regions of the
genome[5]. As the cost of sequencing is decreasing, whole genome sequencing of numerous
and diverse patient samples has become more practical. This has enabled the creation of the
PanCancer Analysis of Whole Genomes (PCAWG), a data base of 2,500 patient-derived tumor
sequencing profiles of various cancer subtypes[6].
2.3 Mutation Types
There are numerous types of mutations and other genetic alterations that directly ini-
tiate tumorigenesis[3]. Single nucleotide variations (SNVs) result from the insertion, deletion
or subsitution of a single nucleotide and are the most common genomic mutations. SNVs in
non-coding regions of the genome can result in aberrant activity of promoters, enhancers, and
silencers. SNVs in coding regions are typically single nucleotide substitutions that change a
three-base amino acid codon sequence resulting in either the production of the same amino acid
(silent mutation), a different amino acid (missense mutation), or a stop codon (truncating muta-
tion). Missense and truncating mutations are more deleterious because they change the amino
acid composition of a protein. Insertions and deletions of nulceotides in the coding sequences
can also affect protein composition by causing a frameshift mutation that typically results in
an early stop codon and thus, a truncated protein product. Copy number alterations are large
deletions or amplifications of a genomic region that result in either decreased or excessive pro-
tein production. Gene fusions occur when two genes at the DNA level are joined through a
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translocation, interstitial deletion, or chromosomal inversion and produce a chimeric protein.
2.4 Machine Learning
There are two types of machine learning: unsupervised and supervised. Unsupervised
machine learning is a method that finds new patterns in a dataset without pre-existing labels and
is typically used in cancer genomics to identify subtypes or clusters of tumors that share a sim-
ilar set of features. Supervised learning is used when a computer algorithm cannot be used to
solve a given problem without implementing example data or previous experiences[7]. A super-
vised machine learning method builds a model by defining a set of features and labels for each
data point or observation in an example dataset. There are many types of supervised machine
learning such as linear regression, logistic regression, random forest and neural networks.[7].
To illustrate the utility of supervised machine learning, consider an example in which a logistic
regression model is used to distinguish between different species of flowers. The length and
width of the sepals and petals may be considered flower features and the flower species (a label)
is assigned to each flower based on their specific features. The model is trained on this existing
data, known as training data, and can be used to further predict the species of a new flower
given its sepal and petal measurements. In this thesis, I present my work based on similar prin-
ciples of machine learning to determine a tumor’s mutation status based on gene expression or
methylation data and determine which features are most important for tumor classification.
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2.5 Modeling Imbalanced datasets
Biological data is often imbalanced, leading to difficulty in building accurate clas-
sification models. In cancer genomic data, there is more data collected from tumors of par-
ticular subtypes, usually those subtypes exhibiting well-studied genetic mutations, like PTEN
or BRCA. This leads to misleading analysis results when metrics are not weighed per class.
For example, when using such data to classify multiple different tumor subtypes, a model may
achieve better overall accuracy by classifying both the larger and smaller classes as the larger
class. Thus, it is imperative that the correct accuracy metric is chosen to avoid a false depiction
of good accuracy. The Receiver Operating Characteristic Area Under the Curve (ROC AUC)
is a very popular metric but is highly inaccurate for imbalanced models because it relies on
the true positive rate and false positive rate, the later being weighted for the negative class[8].
Overall, this results in the inaccurate measurement of false positives. To further explore the
cause of this defect, imagine classifying a dataset with a 5-95 (true-false) split. If the classifier
guessed all 5 true positives as positive but classified 5 false positives as positive as well, then
the false positive rate for the ROC curve would be 5/95, or 0.0526, which is very low. Although
only 0.0526 of the negative class was incorrectly classified, equal numbers of samples were
guessed wrong as were guessed right therefore, this classification is unreliable. Usually in the
case of imbalanced classes, there is more concern with how well the classifier can identify the
smaller class or classes. When trying to model a rare genetic mutation, accurately determining
the mutated samples is crucial for analysis while the negative class is of little interest. In this
situation, it is best to use precision and recall to measure accuracy of imbalanced classification
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models because they are weighted for only the positive class. Precision is a measure of the false
positives that is weighted for the positive class. This quantifies how often a model incorrectly
guessed a negative label as a positive per the number of true positive samples. In the example
above where the false positive rate was only 0.0526, the precision is 0.5 (false positives/(correct
true positives+false positives)). With a precision of only 0.5, it would most likely be necessary
to discredit the classification model. Recall is the true positive rate; it measures how often the
model accurately identifies the positive labels as positive per the number of true positives. To-
gether, these two metrics can be used to create either an F1 score, which is the harmonic mean
of precision and recall, or a precision-recall area under the curve(PR AUC)[8]. When classify-
ing imbalanced datasets, precision-recall AUC or F1 scores can be used to add a description of
the model’s accuracy.
2.6 Driver Discovery Tools
There are several existing computational tools that try to decipher driver from passen-
ger mutations[9]. EPoC uses network modeling of the transcriptional effects of copy number
aberrations to identify driver mutations in glioblastoma (GBM)[10]. DriverNet employs a prob-
abilistic model to locate driver mutations using transcriptional networks[11]. These methods
can predict novel drivers given a set of SNVs or copy number alterations and the corresponding
mRNA gene expression data. In addition, there are methods that identify modules of driver
genes based on mutual exclusivity in certain tumor types, such as CoMEt[12] and MEMo, the
latter of which incorporates prior knowledge such as pathway data into driver gene module
8
discovery[13].
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Chapter 3
Accurate Fusion Detection
3.1 Introduction
Genomic rearrangements in cancer cells produce fusion transcripts that may give rise
to protein products not present in normal cells. These can serve as robust diagnostic markers,
e.g. TMPRSS2-ERG in prostate cancer[14] or drug targets, e.g. BCR-ABL1 in chronic myeloid
leukemia[15]. Ongoing research efforts are beginning to unveil the potential clinical relevance
of aberrant processing of RNA in cancer, such as defects in alternative-splicing. An assortment
of computational methods are needed to fully document the transcriptomic differences between
tumor cells and their normal counterparts. Increasing the alterome of tumors by fully character-
izing their RNA landscapes will expand our understanding of cancer mechanisms, provide new
biomarkers and reveal possible new RNA-based therapeutics, improving personalized patient
treatment.
Gene fusions occur when two genes at the DNA level are joined through a translo-
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cation, interstitial deletion, or chromosomal inversion. A fusion may also occur at the RNA
level, resulting from a ligation between two transcripts. Gene fusions often play an important
role in the initial steps of tumorigenesis. Specifically, gene fusions have been found to be the
driver mutations in neoplasia and have been linked to various tumour subtypes. An increasing
number of gene fusions are being recognized as important diagnostic and prognostic parameters
in malignant haematological disorders and childhood sarcomas. Reviews have estimated that
gene fusions occur in all malignancies and that 20% of human cancer cases harbour at least one
to RNA fusion events[16, 17].
The goal of this challenge is to use a crowd-based competition to identify the opti-
mal methods for quantifying isoforms and detecting mRNA fusions from RNA-seq data. Sev-
eral methods have been published that detect and quantify cancer-associated RNA abundance
species. Yet, it is not clear which methods are best used and under what contexts. Recent
systematic comparisons have been performed[18, 19] to evaluate RNA-Seq analysis methods.
Most comparisons have been performed by an author of one of the competing methods and so
may suffer self assessment bias. One of the more recent evaluations, performed by an impartial
list, was the study by Kumar et al 2016 that compared 12 different methods based on their accu-
racy, length of execution time, and memory requirements. The work performed by the authors
in Creason, et al, includes several newly developed tools, the use of spike-ins for an unbiased
assessment of sensitivity, an objective evaluation framework in which the administrators ran
submitted methods to generate all predictions, and a statistical procedure to infer background
fusions to accurately measure precision. In addition to a new evaluation of methods, our work
provides a tool for simulating RNA isoforms and fusions, a new benchmark dataset against
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which forthcoming methods can be compared, and all of the tested methods in standardized
workflow for re-execution, which should further progress this area of study. My contribution
to the community challenge was to rank the isoform challenge and run a feature importance
pipeline on the fusion detection methods.
3.2 Dream Challenge Results
The fusion detection evaluation challenge received 63 entries, of which the organizers
were able to run 37. The final evaluation consisted of 17 entries, which included multiple sub-
missions by the same team (up to three per team allowed). Two different datasets were created
to evaluate methods-a computationally simulated dataset and another experimentally generated
set using spike-ins (Figure 2a). The simulated dataset was used to evacuate the preliminary
rounds. The simulated data were generated with the program rnaseqSim (in preparation) that
created synthetic reads from computationally constructed fusions. On average, the simulated
tumor samples contained 39 fusions per transcriptome. The second evaluation dataset of spike-
ins was used for the final evaluation of methods. The spike-in data were created in the lab using
a prescribed series of fusion products spiked in to several cancer cell lines, using 18 different
fusion constructs. Scoring of the fusion methods was performed using the F1 score against the
spike-in set. To account for fusions found in the cell line background, fusions called by mul-
tiple methods across multiple replicates were collected for PCR based validation, and utilized
as an imputed truth set to augment the spike-in set (see methods). An additional F1 score was
calculated for the combined (spike-in plus imputed) truth set. All submitted entries were ranked
12
according to their F1 score on the combined data. Two of the submitted methods emerged as
the overall winners of this sub-challenge – Arriba and STAR-Fusion – based on their perfor-
mance in spike-in benchmarks with the addition of the imputed truth set. Arriba achieved an
F1 of 0.73, and STAR-Fusion had an F1 of 0.70. The next closest entry, another permutation
of STAR-Fusion, was at 0.63. Based on a bootstrap analysis, no other methods were found to
have achieved results as accurate as these top two entries. The next method, not submitted by
one of the winning teams was fusioncatcher, submitted by the challenge administrators, at 0.58.
Finally, the highest scoring method, not submitted by the top two teams or the administrators,
was STAR-SEQR with an F1 of 0.47.
3.3 Features Influencing the Accuracy of Fusion Detection Meth-
ods
In an effort to determine what factors influence methods to incorrectly call fusion
events, I created a fusion feature importance pipeline, similar to what was done for the SMC-
DNA challenge[20]. To start, I collected 128 genomic features for each predicted fusion event,
including gene length, transcript length, distance from the breakpoint to repeats, and the abun-
dance for each fusion partner. Next, I built a random forest (RF) classification model to predict
the false-positive fusion events from each submission. The RF was trained to select features
that predict when a method erroneously calls a fusion event when no such event was present
according to the i-truth. Also, I built a second RF model to select features that predict false
negative events; i.e. the RF predicts when a method fails to detect a spiked-in fusion construct.
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To determine feature importance among our classification models I applied our random forest
models to the algorithm Boruta, an all relevant feature selection algorithm[21][22](Figure 3.1).
Boruta determines feature relevance by comparing the original importance with the
importance achievable at random, estimated using permuted versions of a feature, and progres-
sively eliminating irrelevant features to stabilise the test. In order to determine the features
most relevant to all the methods, Iincluded the submission ID as a feature and created one false
positive classification model achieving an out-of-bag (OOB) error rate of only 0.26%. The
false negative RF model was more difficult to predict due to fewer observations, but achieved
an error rate of 7.64%. The Boruta algorithm revealed that the number of transcripts and GC
content were the most important features for determining the false positives among all fusion
methods whereas submission id, coverage across junction and expression were the top fea-
tures for the false negative model(Figure 3.2). Further analysis of the top features for the false
negative model revealed a marked decrease in coverage and expression for the false negative
fusions(Figure 3.3).
3.4 Conclusion
Here I presented some of the results of the SMC-RNA DREAM challenge in which
we synthetically introduced fusions and asked contestants to run fusion detection methods and
report the results. Through my feature importance analysis I determined that coverage, expres-
sion, GC content, and the number of transcripts of each fusion partners are the most important
features. Identifying alterations in tumor sequence data is very important, but even more so is
14
8399080_STARSEQRv050_m
erged_
8040408_genom
ehacke
r_
w
o
rkflo
9609498_sm
cFusion_Hera
_
w
o
rkf
9609499_sm
cFusion_Hera
_
w
o
rkf
8645203_uhrigs−sm
c−rn
a
−fusio
9609502_uhrigs−sm
c−rn
a
−fusio
8645601
8645625
8281648_W
interfell Fusion F
e
8396553
9609508_uhrigs−sm
c−rn
a
−fusio
8114525
9610272_STARSEQRv060_m
erged_
8517255_fusioncatcher_1
8644608_F
o
xtrot
9610021_sm
cFusion.M
ay2017.W
i
Unknown_repeats_1500_2000
scRNA_repeats_2000_2500
LINE_repeats_0_500
DNA_repeats_2000_2500
last_partner_last_exon
DNA_repeats_500_1000
DNA_repeats_1000_1500
DNA_repeats_1500_2000
LTR_repeats_500_1000
LTR_repeats_1500_2000
LINE_repeats_2000_2500
Simple_repeat_repeats_2000_2500
LTR_repeats_1000_1500
cell_line
LTR_repeats_2000_2500
LTR_repeats_0_500
DNA_repeats_0_500
Simple_repeat_repeats_1500_2000
Low_complexity_repeats_1500_2000
Simple_repeat_repeats_500_1000
Low_complexity_repeats_500_1000
Low_complexity_repeats_2000_2500
Simple_repeat_repeats_0_500
LINE_repeats_500_1000
LINE_repeats_1500_2000
Low_complexity_repeats_1000_1500
first_partner_first_exon
LINE_repeats_1000_1500
SINE_repeats_2000_2500
SINE_repeats_1500_2000
Low_complexity_repeats_0_500
Simple_repeat_repeats_1000_1500
SINE_repeats_0_500
SINE_repeats_500_1000
SINE_repeats_1000_1500
Acceptor_GC_content_w_introns
Acceptor_GC_content_wo_introns
Donor_Num_Transcripts_1
Donor_GC_content_wo_introns
Donor_Gene_Size
Donor_Trscpt_Size_w_introns
Acceptor_Num_Transcripts_2
Acceptor_Num_Exons
Donor_Expression
Donor_Num_Exons
Donor_GC_content_w_introns
Acceptor_Expression
Acceptor_Gene_Size
Acceptor_Trscpt_Size_w_introns
Donor_Trscpt_Size_wo_introns
Acceptor_Trscpt_Size_wo_introns
Actual.F1.score
FP.Model.F1.score FP.Model.F1.score
0.95
0.85
Actual.F1.score
0.75
0.5
0
5
10
15
20
25
30
35
(a) False Positive Feature Importance
8040408_genom
ehacke
r_
w
o
rkflo
8114525
8399080_STARSEQRv050_m
erged_
9610272_STARSEQRv060_m
erged_
8517255_fusioncatcher_1
9609498_sm
cFusion_Hera
_
w
o
rkf
9609499_sm
cFusion_Hera
_
w
o
rkf
8281648_W
interfell Fusion F
e
9610021_sm
cFusion.M
ay2017.W
i
8645601
8645625
8645203_uhrigs−sm
c−rn
a
−fusio
9609502_uhrigs−sm
c−rn
a
−fusio
8644608_F
o
xtrot
8396553
9609508_uhrigs−sm
c−rn
a
−fusio
LTR_repeats_500_1000
Acceptor_Trscpt_Size_w_introns
Acceptor_Trscpt_Size_wo_introns
Donor_GC_content_w_introns
Acceptor_GC_content_w_introns
Donor_Trscpt_Size_wo_introns
Donor_Gene_Size
Donor_Trscpt_Size_w_introns
Donor_Num_Transcripts_1
Acceptor_Gene_Size
Acceptor_GC_content_wo_introns
Acceptor_Num_Exons
Donor_Num_Exons
Donor_GC_content_wo_introns
SINE_repeats_1500_2000
Acceptor_Num_Transcripts_2
LTR_repeats_2000_2500
LINE_repeats_0_500
LTR_repeats_1500_2000
DNA_repeats_1000_1500
Low_complexity_repeats_1000_1500
Low_complexity_repeats_500_1000
DNA_repeats_1500_2000
spiked_in_amt
SINE_repeats_500_1000
LINE_repeats_1500_2000
DNA_repeats_500_1000
Low_complexity_repeats_0_500
LINE_repeats_1000_1500
SINE_repeats_1000_1500
SINE_repeats_2000_2500
LINE_repeats_500_1000
SINE_repeats_0_500
LINE_repeats_2000_2500
Junction_Coverage
Donor_Expression
Acceptor_Expression
Donor_Coverage
Acceptor_Coverage
Actual.F1.score
FP.Model.F1.score FP.Model.F1.score
0.92
0.86
Actual.F1.score
0.65
0.4
0
5
10
15
20
25
(b) False Negative Feature Importance
Figure 3.1: Boruta Feature Importance Analysis By Fusion Submission. Heatmap show-
ing results from performing the Boruta algorithm on each submissions false positive fusion
events(A) and false negative fusion events(B). Each cell in the heatmap represents the Z-score
Mean Decrease in Accuracy. Higher Z-scores are in red and represent more important features.
Rows are the fusion submission names and columns are the features. Only features which had
a mean value greater than Borutas shadow max value are shown.
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(b) False Negative Feature Importance
Figure 3.2: Boruta Feature Importance Analysis Across All Fusion Submissions for the
False Positive Model(A) and False Negative Model(B). Boxplot showing results from per-
forming the Boruta Algorithm on all fusion submissions. The y-axis represents the Z-score
MDA and features are across the x-axis. The red plots are the Z-scores of the actual features
and blue are Borutas shadow features which are considered the randomized background fea-
tures. Only features which performed significantly better (p < .05) than the shadow features
are shown in this plot.
determining if these alterations would be considered drivers and contribute to tumorigenesis. Is
it possible that a fusion event is capable of driving cancer? What other events could be driving
cancer and how can we identify them?
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Figure 3.3: False Negative Feature Analysis T Statistic. Students t-test of top features iden-
tified by False Negative Random Forest model. Students t-test was performed individually on
the 5 features comparing false negative fusions missed by the submission methods to the ac-
curately identified fusions. A negative t statistic represents a decrease in the feature values for
false negative fusions.
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Chapter 4
LURE: Classifying Coding Variants of
Unknown Significance
LURE (Learning UnRealized Events): Finding New(or Equivalent) Driver Mutation
Events using Supervised Machine Learning
4.1 Introduction/Background
There are several existing computational tools that try to decipher driver from passen-
ger mutations[9]. EPoC uses network modeling of the transcriptional effects of copy number
aberrations to identify driver mutations in glioblastoma (GBM)[10]. DriverNet employs a prob-
abilistic model to locate driver mutations using transcriptional networks[11]. These methods
can predict novel drivers given a set of SNVs or copy number alterations and the corresponding
mRNA gene expression data. In addition, there are methods that identify modules of driver
genes based on mutual exclusivity in certain tumor types, such as CoMEt[12] and MEMo, the
18
latter of which incorporates prior knowledge such as pathway data into driver gene module
discovery[13]. In contrast, LURE uses mRNA data to identify mutations in “driver-unknown”
samples with similar expression signatures to known drivers, thereby implicating a novel set of
mutations as possible drivers.
Several studies have built gene expression signatures to identify samples with certain
driver events. For example, studies have identified a TP53 gene expression signature as a re-
liable and independent predictor of disease outcome in breast cancer[23, 24]. In addition, in
patients with epithelial ovarian cancer, a BRCAness gene expression signature is just as pre-
dictive of chemotherapy responsiveness and outcome as mutation status.[25] While creating
signatures as prognostic markers to guide treatment is important in a clinical setting, there has
been little work using such gene expression signatures to find related mutational events. LURE
identifies gene expression signatures across the 723 COSMIC cancer genes[26] and then uses
iterative semi-supervised learning to discover potentially related events.
A similar method, REVEALER is a computational method that identifies combina-
tions of genomic alterations correlated with functional phenotypes, such as the activation or
gene dependency of oncogenic pathways or sensitivity to a drug treatment[27]. While the con-
cept of REVEALER is very similar to LURE, there are few differences which make LURE
better. For one, at every iteration of the process LURE produces a new classification model
slightly more accurate than the previous as the newly discovered events are no longer false
positives and now aide in determining features relevant to the signature. Second, REVEALER
utilizes a mutual exclusive relationship between new events which may limit results as muta-
tion calls are not 100% accurate. Allowing some overlap between predicted events LURE can
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account for possible mutation call errors and identify modules containing co mutated events. In
an effort to compare methods, my undergraduate mentee, Ruikang Tao ran REVEALER using
one of our test sets described in our positive controls and REVEALER was unable to identify
the leave-out test sets (Supplemental Figure 4.1).
4.2 Method
LURE attempts to associate alterations between samples by finding similar signatures
in feature data such as mRNA expression data. LURE achieves this by training a classifier using
the samples of a known driver mutation (the bait) applying it to find ”bait”-absent samples with
a high classifier score, and looking for other alterations (the ”catch”) in those samples that
correlate with the high classifier score.
The first step (Step 0) is to establish a known driver mutation as the initial bait, for
example event A (Figure 4.2A,E). In the next step (Step 1) LURE trains a logistic regression
classification model using gene expression as features and bait mutation status as the label to
be predicted. A cross-validation is run for the classification task and baits can be filtered by
model performance, e.g. area under the precision recall curve (PR AUC). LURE then uses the
classification model to score each sample in the dataset (Figure 4.2A,E). Notwithstanding the
inherent bias towards overfitting, there might be some negative samples not mutated in the bait
gene that still receive a high classifier score. These false positives from the classification task
show the same expression signal as the bait-mutated samples hinting to a different driver event
having a similar effect on the cancer cells.
20
REVEALER − Iteration: 1
TARGET: LGG IC / CIC
SUMMARY SEED: 0.75
SEED: IDH1_test_set1_set1 0.75
Top 4 Matches
CARS_del 11p15.5 
HRAS_del 11p15.5 
TP53_missense 17p13.1 
ATRX_truncating Xq21.1 
CIC p−val FDR
0.2 <7e−05 0
0.21 <7e−05 0
0.25 <7e−05 0
0.25 <7e−05 0
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Figure 4.1: REVEALER results of using IDH1 positive control test sets. Each column
represents the samples in the TCGA Lower Grade Glioma (LGG) dataset. The top row is the
classifier score assigned to each sample using an initial classifier trained on the first IDH1 test
set of 150 samples. The tick marks in the seed row represent the 150 IDH1 test set samples.
REVEALER identified 4 matches, ATRX truncating mutations, TP53 missense mutations, and
a 11p15.5 focal deletion. While these are not invalid results as it has correctly found genes
co-mutated with IDH1, it was unable to find the 60 left out IDH1 mutants.
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Therefore, in Step 2, LURE takes the false positive samples and the rest of the nega-
tive samples and runs SSEA (Sample Set Enrichment Analysis). Our SSEA runs the GSEAPre-
ranked tool in which the mutation status forms sample sets and the classification score is the
sample ranking. SSEA tests each mutation event if the samples having that mutation are associ-
ated with the false positive samples (Figure 4.2A). The events with significant SSEA association
are called ”catch” events. For each catch event, LURE then combines the positive samples for
both catch and bait event into a new, intermediate bait event and trains a new classifier for these
samples (Figure 4.2B,E). A cross-validation is run for the new classification model and the PR
AUC results are compared to the initial classifier to ensure the model improves when including
the new positive samples (Student’s t-test t-statistic > 0). In addition, the new classifier has to
outperform a null model background distribution by adding the same number of randomly cho-
sen catch samples to the true positives and running a cross-validation (Student’s t-test p-value
< .05). After establishing that the new additional event both improves the original classifier
and significantly outperforms a random background distribution, the new classifier is run on all
samples again (Figure 4.2B,E) in an effort to search for the next set of catch events. This itera-
tive event discovery builds new classifiers by adding one catch event at a time until no further
events are found by SSEA or classifier performance is not increased anymore. LURE builds an
Event Discovery Tree and recursively returns to the root after exploring all events at each node
(Figure 4.2C).
In Step 3 LURE builds a final classification model from the union of all events in
the event discovery tree. It then runs a set coverage algorithm between all events in the event
discovery tree and the samples predicted to be positive by the final classification model (Fig-
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ure 4.2D,E). The set coverage algorithm identifies the minimum set of events which cover all
the positive samples allowing us to remove completely overlapping mutations. The minimal set
of events representing the positive samples is called the ”Catch” Cover.
4.3 Results
4.3.1 TCGA Positive Controls
Splicing Factor 3b Subunit 1 (SF3B1) is a well known splicing factor which is recur-
rently mutated in many tumor types, including Uveal Melanoma (UVM). Missense mutations
in SF3B1 leads to aberrant splicing and a unique gene expression signature[28]. In order to test
LURE’s ability to discover known ’catch’ events, I created a test set of bait and catch events
using SF3B1 missense mutations in the TCGA UVM sample set. Of the 80 UVM samples, 18
samples have missense mutations in SF3B1. I created an initial bait out of 8 of those samples
and left out 2 sets of 5 SF3B1-mutated samples for discovery. LURE re-discovered both held
out sets correctly, collecting all of the SF3B1 missense events in the Catch Cover (Figure 4.3A).
Isocitrate Dehydrogenase 1 (IDH1) is one of three isocitrate dehydrogenase isozymes,
which when mutated causes hypermethylation and subsequent altered gene expression in Gliomas[29].
I chose this driver gene as another positive control and created a test set using IDH1 mutations
in the TCGA Lower Grade Glioma (LGG) sample set. Of the 210 LGG samples with an IDH1
missense mutation, I created an initial bait with 150 samples and three sets of 20 samples as
potential catch events. LURE collected all three of the left out events in the Catch Cover, as
well as including the IDH2 missense mutation event. IDH2 is another one of the three IDH
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Figure 4.2: LURE Method. (A) LURE Oncoprint of Bait Mutation A. Triangle symbol
represents the classification model for samples having event A. Barplot showing the score given
to each sample by the model representing the probability the sample has the mutation event
A. The annotation bars below indicate mutations present in each sample. The check mark
annotations on the right mark if events passed Sample Set Enrichment Analysis (SSEA, see
Supplemental Methods) (p < .05, fdr < .25). (B) LURE Oncoprint of Intermediate Bait
Mutation A:C. Results from a classification model containing both events A and C. (C) LURE
Event Discovery Tree. Directed graph shows LURE’s iterative Event Discovery Tree. Each
node is a classification model built on the events shown in the triangle symbol within each node.
The blue circles within each node represent the newest event added to the model. (D) LURE
Set Cover Algorithm. Bipartite graph shows the result of running a Set Cover Algorithm on
the mutations collected from the Event Discovery Tree and the samples predicted to be mutated
in these genes by the final classification model. The red node and edges mark Event F, which
is completely overlapping with other mutations and therefore removed from the final event set
(’Catch’ Cover). (E) LURE Method Flowchart.
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Figure 4.3: LURE Bait and Catch Oncoprints of positive controls. Samples are represented
across the rows. Colored tick marks represent the different types of alterations present in the
samples. Barplot on top shows the LURE classifier score for each sample after the final iteration.
(A) SF3B1 test set in UVM. Initial bait is set to 8 SF3B1 missense in UVM, and LURE finds
the 2 left out sets of 5 each. (B) IDH1 test set in LGG. Initial bait is set to 150 samples of
IDH1 Missense in LGG and Lure finds the 3 left out sets of 20 each.
isozymes and a mutation has the same oncogenic effect as an IDH1 mutation[30](Figure 4.3B).
4.3.2 LURE on the PANCAN Dataset
In order to look for novel associations between genes already associated with cancer,
I decided to run LURE across all tumor types in TCGA, the Pan-Cancer dataset, restricting
both baits and catches to mutation events in the 723 COSMIC genes[26]. I created bait events
for missense mutations, truncating mutations, homozygous focal point copy number deletions,
splice site mutations, and gene fusions and required at least 10 alterations per tumor type. I
restricted our classification models to within tumor types, as different tumor types typically
have unique expression patterns so unless our mutation status was equally stratified across tumor
types our models would simply predict tumor type and not mutation status. By creating baits for
different alteration types in the same gene, as opposed to one bait for any alteration in a gene,
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I are able to identify associations between different alteration types of the same gene as well as
identify functional alterations. For example, -thalassemia mental retardation X-linked (ATRX),
a gene recurrently mutated in Lower Grade Gliomas (LGG), only has an oncogenic effect with
a loss of function mutation, either truncating mutation or copy number loss, whereas a missense
mutation may not have an effect[30]. I then trained logistic regression models on the resulting
3,053 bait/tumor type combinations.
I tested both random forest and neural network and found the linear model to con-
sistently score higher in the majority of models (Suppl. Figure 1-Rick’s Figure). In order to
limit the number of putative false positive results, I restricted the number of bait classifiers by
considering only those with PR AUC > 0.5, precision > 0.4, and recall > 0.75 (Supplemen-
tal Figure 4.4). Since the objective of LURE is to classify false positives, I were more lenient
with the precision and placed more restriction on the recall. Among the bait classifiers passing
these thresholds, the most common bait across all tumor types was TP53, and the tumor types
with the highest number of passing bait classifiers were Lower Grade Glioma (LGG), Thyroid
Carcinoma (THCA), and Prostate Adenocarcinoma (PRAD) (Supplemental Figure 4.6) After
trimming the models, I ran LURE with the 81 remaining baits (Figure: 4.5) using missense mu-
tations, truncating mutations, splice site mutations, gene fusions, and focal point copy number
amplifications and homozygous deletions of COSMIC genes as possible catches.
LURE found significant catch-associations for 35 of the 81 baits tested. By adding
catches to each initial bait event, the classifier PR AUC was increased in varying amounts across
the different baits (Supp Figure 4.7A). The most common bait among the 35 were associations
with TP53 (Supp Figure 4.7E). Tumor type was evenly distributed and SNVs dominated the
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Figure 4.4: Histogram of Bait Precision-Recall Area Under the Curve. Plot shows a his-
togram of the 3,053 Precision Recall AUC cross validation scores from training a tumor type
specific logistic regression classifier on the different 723 COSMIC genes. Classifiers were cre-
ated only in tumor types with more than 10 alterations.
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Figure 4.5: Barplot of 81 Bait Classifiers. Barplot shows Precision-Recall AUC test scores for
81 bait-tumor type classifiers. Bar is colored by tumor type.
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Figure 4.6: Heatmap of baits used in PANCAN LURE analysis. Rows are bait and alteration
type, and the columns are tumor type. Each cell in the heatmap corresponds to the PR AUC
score of that bait/alteration/tumor type classifier. The higher scoring baits are in red/orange and
blue denotes no classifier due to lack of alterations in that bait tissue combination. TP53 was
the most common bait across tissues and the tumor types with highest number of high scoring
baits were LGG, THCA, PRAD.
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bait mutation type (Supp Figure 4.7F).
Among the high confidence results with a final classifier PR AUC > 0.8, 14 of 59
associations were between different alterations types within the same gene, such as TP53 trun-
cating, splice site, and missense mutations in various tumor types (Figure 4.8). There were four
associations within the same gene families, e.g. IDH1/2 or the RAS protein family. In addi-
tion, I identified gene fusion events partners in BRAF and RET which associated with BRAF
missense mutation in THCA. I also identified that for 20 of the 59 high confidence bait-catch
associations both genes were present in the same human pathway gene set (not regarding gene
sets with > 1000 genes)[?].
When all Pan-Cancer results are considered, the resulting association network does
not group by tumor type but surprisingly by pathway (Suppl. Figure showing large cytoscape
plot), and in particular four canonical pathways emerge (Figure 4.9). LURE identified very
interesting associations for PTEN, in particular between PTEN and CTNNB1, a connection
supported by recent research which suggests PTEN plays a role in regulating the subcellular
localization of β-catenin[31]. Another striking association is between PTEN and EGFR, for
which recent findings provide evidence that PTEN regulates EGFR signaling[32]. These LURE
associations for PTEN reveal cross talk between pathways and provide further evidence that
alterations in PTEN influence EGFR signaling and/or β-catenin signaling.
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Figure 4.7: Bait Catch Association Data Panel. Panel shows bait and catch annotations for
the 35 baits in which associations were found. Baits are across the x-axis and sorted by final
Bait and Catch PR AUC. (A) Precision Recall Area Under the Curve. Stacked bar plot shows
the original PR AUC score of the bait and the final PR AUC score including the new catch.
(B) Number of Samples Stacked bar plot shows the number of samples in the bait and the
additional samples in the catch. (C) Tumor Type. Annotation bar shows the tumor type in
which the bait-catch association was found.(D) Bait Mutation Type. Annotation bar shows the
type of bait mutation. (E) Bait Gene Name. Annotation bar shows the name of the bait gene.
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Figure 4.8: High Confident LURE PANCAN Results. Sankey plot shows the high confident
18 bait-catch associations with a final PR AUC greater than 0.8. Bait gene and mutation type
are on the left side and the Catch bait gene and mutation type are on the right side. The flows
represent an association between the bait and catch gene. The color of the left side of each flow
is the tumor type in which each association was found. The color of the right side of each flow
is the association type.
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Figure 4.9: LURE ”Event Net” of LURE PANCAN Results LURE Event Net shows all
associations resulting from the 35 successful cosmic bait genes. Edges are colored by the tumor
type in which the association was found. Edges are directed from Bait to Catch. Pathway
associations are annotated with circles.
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4.3.3 LURE finds new drivers of the Alternative Lengthening of Telomeres in
Sarcomas
Tumors must employ Telomere Maintenance Mechanisms (TMM) to extend their
telomeres in order to avoid senescence and multiply rapidly[33]. To date, there are two known
mechanisms which tumor cells use to avoid telomere erosion: the overexpression of telomerase,
an enzyme with the ability to extend telomeres, or the Alternative Lengthening of Telomeres
(ALT) pathway. The vast majority of tumors overexpress telomerase in some way, whereas a
small portion (10-15%) use ALT[34]. ALT+ samples lengthen telomeres through homologous
recombination, mediated by loss-of-function mutations in the ATRX and DAXX genes[35]. Ap-
proximately 80% of tumors with ALT harbor mutations in ATRX or DAXX[36] leaving 20%
with no known driver and in particular there are Lower Grade Glioma tumor samples which do
not harbor a mutation in ATRX or the TERT promoter[37]. Using LURE, I sought to identify
new driver mutations of ALT pathway using gene expression signatures of samples harboring
ATRX loss of function mutations. Sarcomas and Lower Grade Gliomas have the highest preva-
lence of ALT+ samples, and ATRX is recurrently mutated, so I chose these tumor types to
search for new drivers of the ALT pathway[35]. I restricted our gene set to a manually curated
set of genes associated with telomere maintenance from the TelNet database[38], therefore I
can expect results of telomere associated genes, but in particular I am looking for associations
with ALT. Since TP53 is commonly mutated in ALT-positive (ALT+) samples and is not known
to solely cause ALT[39], I decided to exclude any TP53 alterations in the possible catches in an
effort to hone in on new ALT drivers.
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Using ATRX truncating mutations as bait, LURE associated four mutations in Sarco-
mas (Figure 4.10A). While it is expected to associate ATRX truncating mutations with a ATRX
copy number deletion[37], the deletions in RB1 and SP100 are novel results. I suggest the ex-
pression signature LURE identified in this analysis is classifying ALT+ TMM samples and the
associated alterations are possibly driving the TMM. Previous work has associated RB1 alter-
ations with long telomeres in the absence of TERT mutations and ATRX inactivation[40]. In
addition, mouse models have revealed that the knock-out of Rb-family proteins causes elon-
gated telomeres[41]. LURE also identified SP100 deletions as an ALT driver, and while SP100
deletions have not been directly reported to be involved in ALT, overexpression of SP100 in
ALT+ cell lines resulted in suppression of ALT characteristics[42]. I therefore think it is pos-
sible that a SP100 deletion leads to unhindered ALT TMM activity. To further investigate the
subset of LURE classified ALT+ samples, I performed a survival analysis and found the ALT+
samples show a significantly worse prognosis agreeing with recent research[43].
In Lower Grade Gliomas (LGG), also using ATRX truncating mutation as bait, LURE
found similar results identifying associations with other ATRX alterations such as ATRX dele-
tions, splice site, and missense mutations (Suppl. Figure X-oncoprint). Surprisingly, ATRX
missense mutations were associated with truncating and as previously thought these mutations
were not drivers, but this evidence suggests otherwise. Together these findings implicate new
single and/or combinations of driver mutations required for the initiation of the ALT telomere
maintenance mechanism and with further testing could prove to be therapeutic targets.
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Figure 4.10: LURE Oncoprint and Survival Plot. (A) Using a known driver for ALT, ATRX
truncating mutations, for bait in Sarcomas(SARC), LURE found three catch events: copy num-
ber deletions in ATRX, RB1, and SP100. (B) Survival plot shows the ALT classification using
the final set cover classifier from the LURE method.
4.3.4 LURE identifies associations within the MAPK signaling pathway
Oncogenic mutations of the HRAS, NRAS, or KRAS genes are frequently found in
human tumors and known to throw off the normal balance of signaling networks controlling
cellular proliferation, differentiation, and survival. Oncogenic mutations in a number of other
upstream or downstream components of MAPK/RTK signaling pathways, including membrane
receptor tyrosine kinases (RTKs) or cytosolic kinases, have been detected more recently to be
associated with a variety of cancer types[44]. The oncogenic RAS mutations and other mutation
events within the MAPK/RTK signaling pathways are often mutually exclusive, indicating that
the deregulation of Ras-dependent signaling is the essential requirement for tumorigenesis[44].
Previous studies have shown that tumor samples harboring Ras protein mutations have a unique
gene expression signature and Ras-dependent samples can be more accurately defined by us-
ing the signature instead of the mutation status alone.[45] Building on this knowledge I was
able to use LURE to not only train an accurate Ras-dependent classifier as was done in Way
et al[46], but also identify new alterations which may be activating the MAPK/RTK signaling
36
pathway in samples without a Ras protein mutation. To begin I restricted our baits to genes
known to be involved in the MAPK/RTK signaling pathway[47]. Of those initial baits 23 event
classifiers scored greater 0.5. I ran LURE for these 23 bait events and did not place any restric-
tions on the ”catch” set. The resulting ”Event Net” revealed known as well as new associations
(Figure 4.11A). One interesting association found by LURE in Head-Neck Squamous Cell Car-
cinomas (HNSC) is between HRAS missense mutations and a focal deletion in the 2q23.3 locus
(Figure 4.11B). The samples were by and large mutually exclusive with only one sample having
both a 2q23.3 and HRAS alteration and no samples with alterations in either KRAS or NRAS.
Among the 61 genes in the 2q23.3 locus, CHST11 has been shown to regulate MAPK/RTK
pathway activity in hepatocellular carcinoma[48]. I suggest that in the absence of a HRAS mu-
tation, MAPK signaling is activated by a deletion of the 2q23.3 locus in Head-Neck Squamous
Cell Carcinomas (HNSC).
4.3.5 LURE ran on the PCAWG dataset (using classifiers from the PANCAN
dataset)
In an effort to use LURE to find a functional impact of non-coding mutations by as-
sociation with known coding driver mutations I incorporated the new PanCancer Analysis of
Whole Genomes (PCAWG) dataset into our analysis. Using even a larger set of bait classifiers
which included not only the bait classifiers from the previous exercise I also included copy
number alterations. After preparing the bait classifiers, I quantile normalized the two different
datasets to remove any platform batch effects and ran LURE which identified 4 new associa-
tions (Figure 4.12). Of particular interest, the association between MDM2 amplifications and
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Figure 4.11: MAPK LURE Pathway Analysis (A) LURE ”Event Net” showing
MAPK/RTK associations. Each node represents an event. The directed edges represent an
association and the direction of the LURE discovery. The color of each edge represents the
tumor type in which the association was found. (B) LURE Oncoprint of HRAS in HNSC.
Using HRAS as a bait in HNSC, LURE found a delection catch event of the 2q23.3 region.
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coding mutations of TP53 is expected and worked as a positive control. Another association
of CTNNB1 coding mutations with enhancer mutations in PSIP1 enhancer mutations in Liver
Hepatocellular Carcinoma is novel and interesting as there has been recent work correlating
expression between PSIP1 and CTNNB1 in gliomas[49].
4.4 Discussion
Here I presented a new method to classify genomic alterations in tumors with other
well known alterations using a specific feature dataset such as gene expression. This method
works best with a large dataset because in order to build an accurate bait classifier there needs
to be an adequate number of positive samples. In addition, identifying catch samples requires
a fair amount of samples with the same alteration in order to pass the FDR correction in the
sample set enrichment test (SSEA). The most common associations found with LURE in the
PANCAN analysis were between different alteration types within the same gene, such as TP53.
Also a considerable amount of associations were found within the same gene family as well
as pathway. In addition to associating known alterations across PANCAN, I also demonstrated
LURE’s ability to find novel drivers of the ALT TMM and the MAPK/RTK pathway. LURE’s
inability to find novel non-coding associations with coding variants lies in the fact the power
was lacking in the smaller number of non-coding tumor samples. I believe there needs to be
an increase of whole genome sequencing of tumors in order to correlate non-coding mutations
with coding.
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Figure 4.12: Alluvial Plot of LURE PCAWG Results. The left side of the plot shows the Baits
and the right side shows Catches. The flow represents the tumor type in which an association
was discovered by LURE.
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Chapter 5
Non-coding Variant Function Discovery
5.1 Introduction
Over the past decade, cancer genome sequencing efforts such as The Cancer Genome
Atlas (TCGA) have identified millions of somatic genetic aberrations; however, the annotation
and interpretation of these aberrations remains a major challenge[9]. Specifically, while some
aberrations occur frequently in specific cancer types, there is a long tail of rare aberrations
that are difficult to distinguish from random passenger aberrations in modestly sized patient
cohorts[50, 3] In many cancers, a significant proportion of patients do not have known coding
driver mutations[51], suggesting that additional driver mutations remain undiscovered. To date,
the vast majority of known driver mutations affect protein-coding regions. Only a few non-
coding driver mutations, most notably mutations in the TERT promoter[52, 53, 54], have been
identified; somatic expression Quantitative Trait Loci (eQTLs) correlate with gene expression
changes in some cancer types[55]. Recent studies from the Pan-Cancer Analysis of Whole
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Genomes (PCAWG) project of the International Cancer Genome Consortium (ICGC) reveal
few recurrent non-coding drivers in analyses of individual genes and regulatory regions[54].
In this chapter I will discuss a pathway and network analysis of coding and non-
coding somatic mutations from 2,583 tumors from 27 tumor types compiled by the Pan-Cancer
Analysis of Whole Genomes (PCAWG) project of the International Cancer Genome Consortium
(ICGC)[56], the largest collection of uniformly processed cancer whole genomes to date.
In addition to unlocking the non-coding areas of the genome enabling further analysis
of the tumor variants, whole genome sequencing has allowed for sequencing for other regions
such as telomeres to be sequenced. This chapter also includes a discussion on such sequencing
and the analysis I performed confirming results of a possible new driver of the ALT pathway
found by LURE in Sarcomas.
5.2 Using Gene Pathway Networks to Annotate Non-coding Vari-
ants
Cancer driver mutations unlock oncogenic properties of cells by altering the activity
of hallmark pathways[57]. Accordingly, cancer genes are known to cluster in small number of
cellular pathways and interacting subnetworks[3]. Previously, pathway and network analysis
has proven useful for implicating infrequently mutated genes as cancer genes based on their
pathway membership and physical/regulatory interactions with recurrently mutated genes[58,
57]. However, the interactions between coding and non-coding driver mutations have not been
systematically explored.
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In work described elsewhere, Reyna, Haan et al[59] employed seven distinct path-
way and network analysis methods and derived the consensus of the methods predictions as
pathway-implicated driver (PID) genes(Figure 5.1). In total, we identified a consensus set of
93 high-confidence pathway-implicated driver genes using non-coding variants (PID-N) and a
consensus set of 87 pathway-implicated driver genes using coding variants (PID-C)(PID venn
diagram figure). Both sets of PID genes, particularly the PID-N set, contain rarely mutated
genes that were not identified by individual recurrence tests but interact with other well-known
cancer genes. In total, 121 novel PID-N and PID-C genes are revealed as promising candidates,
expanding the landscape of driver mutations in cancer.
Furthermore, we examined the contribution of coding and non-coding mutations in
altering biological processes, finding that while chromatin remodeling and some well-known
signaling and proliferation pathways are altered primarily by coding mutations, other impor-
tant cancer pathways, including developmental pathways such as Wnt and Notch pathways, are
altered by both coding and non-coding mutations in PID genes. Intriguingly, we find many
non-coding mutations in PID-N genes with roles in RNA splicing, and samples with these non-
coding mutations exhibit similar gene expression signatures as samples with well-known coding
mutations in RNA splicing factors(Figure 5.3). I sought to identify an orthogonal analysis sup-
porting the RNA splicing module of non-coding mutants. The splicing module consisted of 17
PID-N genes belonging to splicing-related pathways (pathway oncoprint plot), including several
heterogeneous nuclear ribonucleoproteins (hnNRP) and serine and arginine rich splicing factors
(SRSFs). None of these PID-N genes were significantly mutated according to single-element
tests of the PCAWG driver discovery analysis. I did not find any significant (FDR < 0.1) in
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Figure 5.1: Overview of the pathway and network analysis approach. Coding, non-coding,
and combined gene scores were derived for each gene by aggregating driver p-values from the
PCAWG driver predictions in individual elements, including annotated coding and non-coding
elements (promoter, 5 UTR, 3 UTR, and enhancer). These gene scores were input to five net-
work analysis algorithms (CanIsoNet [Kahraman et al., in preparation], Hierarchical HotNet,
an induced subnetwork analysis [Reyna and Raphael, in preparation], NBDI, and SSA-ME),
which utilize multiple protein-protein interaction networks, and to two pathway analysis algo-
rithms (ActivePathways [Paczkowska, Barenboim et al., in submission] and a hypergeometric
analysis [Vazquez]), which utilize multiple pathway/gene-set databases. We defined a non-
coding value-added (NCVA) procedure to determine genes whose non-coding scores contribute
significantly to the results of the combined coding and non-coding analysis, where NCVA re-
sults for a method augment its results on non-coding data. We defined a consensus procedure
to combine significant pathways and networks identified by these seven algorithms. The 87
pathway-implicated driver genes with coding variants (PID-C) are the set of genes reported by
a majority ( 4/7) of methods on coding data. The 93 pathway-implicated driver genes with non-
coding variants (PID-N) are the set of genes reported by a majority of methods on non-coding
data or in their NCVA results. Only 5 genes (CTNNB1, DDX3X, SF3B1, TGFBR2, TP53) are
both PID-C and PID-N genes.
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Figure 5.2: Overlap of consensus results for pathway and network methods. (A) PID-C and
PID-N genes have negligible overlap. Only 5 genes (CTNNB1, DDX3X, SF3B1, TGFBR2,
TP53 are both PID-C and PID-N genes. (B) Overlap of all consensus results. Four-circle Venn
diagram for the overlap of the consensus results on coding data, i.e., PID-C genes; consensus
pathway/network results on non-coding data; consensus pathway/network results on coding and
non-coding data; and the union of the consensus results on non-coding data and the non-coding
value-added (NCVA) results, i.e., PID-N genes.
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Figure 5.3: Pathway and network modules containing PID-C and PID-N genes. (A) Net-
work of functional interactions between PID-C and PID-N genes. Nodes represent PID-C
and PID-N genes and edges show functional interactions from the ReactomeFI network (grey),
physical protein-protein interactions from the BioGRID network (blue), or interactions recorded
in both networks (purple). Node color indicates PID-C genes (green), PID-N genes (yellow),
or both PID-C and PID-N genes (orange);node size is proportional to the score of the cor-
responding gene; and the pie chart diagram in each node represents the relative proportions
of coding and non-coding cancer mutations associated with the corresponding gene. Dotted
outlines indicate clusters of genes with roles in chromatin organization and cell proliferation,
which predominantly contain PID-C genes; development, which includes comparable amounts
of PID-C and PID-N genes; and RNA splicing, which contains PID-N genes. A core cluster of
genes with many known drivers are also indicated. (B) Pathway modules containing PID-C and
PID-N genes. Each row in the matrix corresponds to a PID-C or PID-N gene, and each column
in the matrix corresponds to a pathway module enriched in PID-C and/or PID-N genes (see
Methods). A filled entry indicates a gene (row) that belongs to one or more pathways (column)
colored according to gene membership in PID-C genes (green), PID-N genes (yellow), or both
PID-C and PID-N genes (orange). A darkly colored entry indicates that a PID-C or PID-N gene
belongs to a pathway that is significantly enriched for PID-C or PID-N genes, respectively. A
lightly colored entry indicates that a PID-C or PID-N gene belongs to a pathway that is signif-
icantly enriched for the union of PID-C and PID-N genes but not for PID-C or PID-N genes
separately. Enrichments are summarized by circles adjacent each pathway module name and
PID gene name. Boxed circles indicate that a pathway module contains a pathway that is signif-
icantly more enriched for the union of the PID-C and PID-N genes than the PID-C and PID-N
results separately. The enriched modules and PID genes are clustered into four biological pro-
cesses: chromatin, development, proliferation, and RNA splicing as indicated, with differing
contributions of PID-C and PID-N genes.
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cis associations between non-coding mutations and altered expression of these genes. Thus,
I explored potential in trans effects on pathway expression changes. I found that non-coding
mutations in splicing-related PID-N genes largely recapitulate a recently published association
by TCGA[1] between coding mutations in several splicing factors and differential expression
of 47 pathways (Figure 5.5). Three clusters of mutations were identified using hierarchical
clustering based on patterns of differential expression (C1, C2, and C3;Figure 5.5). The clus-
ters were found to be robust to the choice of clustering approach as a highly overlapping set
of clusters was produced by t-distributed stochastic neighbor embedding (top annotation bar in
Figure 5.5). Further support for robustness of clusters was found via silhouette scores and boot-
strapping (silhoutte plot). Each of these clusters contained at least one coding mutation in the
splicing genes SF3B1, FUBP1, and RBM10 as reported in [1], with non-coding mutations in
splicing-related PID-N genes showing similar gene expression signatures. The joint analysis of
coding and non-coding mutations in splicing factors also recovered the two groups of enriched
pathways (P1 and P2 in Figure 5A) reported in [1]. One group (P1) is characterized by immune
cell signatures and the other group (P2) reflects mostly cell-autonomous gene signatures of cell
cycle, DDR, and essential cellular machineries[1]. The similarity between the gene expression
signatures for non-coding mutations in several PID-N splicing factors and coding mutations in
splicing factor genes[1] supports a functional role for splicing-related PID-N genes in altering
similar gene expression programs.
This splicing analysis and the other analysis by [59] demonstrates that somatic non-
coding mutations in untranslated and cis-regulatory regions constitute a complementary set of
genetic perturbations with respect to coding mutations, affect several biological pathways and
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AB
Figure 5.4: RNA splicing factors are targeted primarily by non-coding mutations and al-
ter expression of similar pathways as coding mutations in splicing factors. (A) Heatmap
of Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Scores (NES). The
columns of the matrix indicate non-coding mutations in splicing-related PID-N genes and cod-
ing mutations in splicing genes reported in [1] and the rows of the matrix indicate 47 curated
gene sets[1]. Red heatmap entries represent an upregulation of the pathway in the mutant sam-
ples with respect to the non-mutant samples and blue heatmap entries represent a downregula-
tion. The first column annotation indicates mutation cluster membership according to common
pathway regulation. The second column annotation indicates whether a mutation is a non-
coding mutation in a PID-N gene or a coding mutation[1], with the third column annotation
specifies the aberration type (promoter, 5 UTR, 3 UTR, missense, or truncating). The fourth
column annotation indicates the cancer type for coding mutations from [1]. The mutations clus-
ter into 3 groups: C1, C2, and C3. The pathways cluster into two groups[1]: P1 and P2, where
P1 contains an immune signature gene sets and P2 contains cell autonomous gene sets as re-
ported in [1]. (B) tSNE plot of mutated elements illustrates clustering of gene expression
signatures for samples with non-coding mutations in splicing-related PID-N genes with
gene expression signatures for coding mutations in previously published splicing factors.
The shape of each point denotes the mutation cluster assignment (C1, C2, or C3), and the color
represents whether the corresponding gene is a PID-N gene with non-coding mutations or a
splicing factor gene with coding mutations[1].48
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Figure 5.5: Cluster stability analysis. (A) Silhouette scores of pathway clusters 1 and 2.
Silhouette width is on the x-axis, and the 47 pathways across y-axis. Average silhouette score
per cluster is shown to the right of the bar plots. (B) Silhouette scoring of the 3 mutation element
clusters. (C, D) Histograms representing the results of a cluster bootstrapping analysis using
the Jaccard similarity coefficient to identify how often pathways (C) or mutation elements (D)
clustered together in each bootstrap.
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molecular interaction networks, and should be further investigated for their role in the onset and
progression of cancer.
5.3 Unsupervised Classification of Non-coding Telomere Regions
One of the hallmarks of cancer is its ability to evade the normal cellular mechanisms
of senescence[60]. Normal somatic cells typically have finite cell division potential, with telom-
ere attrition one mechanism to limit numbers of mitoses[33]. Cancers enlist multifarious strate-
gies to achieve replicative immortality. Over-expression of the telomerase gene, TERT, which
maintains telomere lengths, is especially prevalent. This can be achieved via point mutations in
the promoter that lead to de novo transcription factor binding[52, 53]; hitching TERT to highly
active regulatory elements elsewhere in the genome[61]; insertions of viral enhancers upstream
of the gene[62]; and increased dosage through chromosomal amplification. In addition, there
is an alternative lengthening of telomeres (ALT) pathway, in which telomeres are lengthened
through homologous recombination, mediated by loss-of-function mutations in the ATRX and
DAXX genes[35].
Overall, 16% of tumours in the PCAWG dataset exhibited somatic mutations in ATRX,
DAXX and/or TERT with a number of altered genes correlating with individual telomeric fea-
tures such as TP53, ATRX, PLCB2, MEN1, TSSC4, RB1, and DAXX. TERT alterations were
detected in 270 samples, whereas 128 tumours had somatic mutations in ATRX or DAXX, of
which 71 were protein-truncating.
Whole genome sequencing includes reads of DNA from the telomeres, which can be
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recognised by the preponderance of the characteristic hexameric repeat, TTAGGG. In work de-
scribed elsewhere in Sieverling, et al, 12 features of telomeric sequence were measured on the
PCAWG cohort, including counts of nine variants of the core hexameric sequence, the num-
ber of ectopic telomere-like insertions within the genome, the number of genomic breakpoints,
and the telomere length as a ratio between tumour and normal. I clustered the PCAWG sam-
ples based on their telomere sequence-associated features, normal and tumour samples formed
distinct, non-overlapping clusters (Figure 5.6), suggesting that the biology of telomere mainte-
nance is nearly universally altered in cancer.
Unexpectedly, I noticed the tumour samples formed four distinct sub-clusters (Figure
5.7A), suggesting a more diverse array of telomere maintenance mechanisms than the usual
TERT/ALT dichotomy. Clusters C1 (47 tumours) and C2 (42 tumours) were enriched for
traits of the ALT pathway, having longer telomeres, more genomic breakpoints, more ectopic
telomere insertions, and variant telomere sequence motifs (Figure 5.8). C1 and C2 were dis-
tinguished from one another by the latter having striking elevation in the number of TTCGGG
and TGAGGG variant motifs among the telomeric hexamers. Samples in clusters C3 (33 tu-
mours) and C4 (2396 tumours) had relatively short telomere lengths, fewer genomic break-
points and more normal frequencies of variant hexamers. Interestingly, samples in C2 and C3
only infrequently underwent whole genome duplication, as opposed to those in C1 and C4
(p < 6.985x10− 6). Thyroid adenocarcinomas were strikingly enriched among C3 samples
(26/33 C3 samples; p < 2.2x10− 16); the C1 cluster (ALT subtype 1) was common among
sarcomas; and both pancreatic endocrine neoplasms and low-grade gliomas had a high propor-
tion of samples in the C2 cluster (ALT subtype 2) (Figure 5.7B). Interestingly, some of the
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Figure 5.6: Differences between normal and cancer-associated telomere properties. Scatter
plot showing the four clusters of telomere patterns identified across PCAWG cancers, together
with the more homogeneous cluster of matched normal samples, generated by t-Distributed
Stochastic Neighbour Embedding.
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thyroid adenocarcinomas and pancreatic neuroendocrine tumours that cluster together (Cluster
C3; (Figure 5.7) have matched normals that also cluster together (Normal cluster N3, Figure
5.6). This suggests that a subtype of these tumor types share telomeric maintenance proper-
ties: for example, the GTAGGG repeat is overrepresented among samples in this group (Ex-
tended Data Figure 19). Somatic driver mutations were also unevenly distributed across the
four clusters (Figure 5.7C). C1 tumours were enriched for RB1 mutations or structural vari-
ants (p=3.1x10-5), as well as frequent structural variants affecting ATRX (p=6x10-14), but not
DAXX. The RB1 and ATRX mutations were, by and large, mutually exclusive (Extended Data
Figure 20A). In contrast, C2 tumours were enriched for somatic point mutations in ATRX and
DAXX (p < 6.4x10−5), but not RB1. The enrichment of RB1 mutations in C1 remained sig-
nificant when only leiomyosarcomas and osteosarcomas were considered, confirming that this
enrichment is not merely a consequence of the different distribution of tumour types across
clusters. C3 samples had frequent TERT promoter mutations (30%; p=2.3x10-6). Patterns of
RB1, ATRX, DAXX and TERT expression confirmed the associations revealed in the mutation
analysis (Figure 5.10B).
The predominance of RB1 mutations in C1 was striking. Nearly a third of the sam-
ples in C1 contained an RB1 alteration, evenly distributed across truncating SNVs, SVs and
shallow deletions, with a mix of clonal and subclonal events (Figure 5.11). Interestingly, pre-
vious work has shown that RB1 mutations are associated with long telomeres in the absence
of TERT mutations and ATRX inactivation[40], and mouse models have revealed that knock-
out of Rb-family proteins causes elongated telomeres[41]. The association with the C1 cluster
here suggests that RB1 mutations can represent another route to activating the ALT pathway.
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Figure 5.7: Telomere sequence patterns across PCAWG. (A) Scatter-plot showing the four
clusters of telomere patterns identified across PCAWG by t-Distributed Stochastic Neighbour
Embedding (tSNE). (B) Distribution of the four clusters of telomere patterns in selected tumour
types from PCAWG. (C) Distribution of relevant driver mutations associated with alternative
lengthening of telomere and normal telomere maintenance across the four clusters. (D) Distri-
bution of telomere maintenance abnormalities across tumour types with more than 40 patients
in PCAWG. Samples classified as tumour cluster 1-3 if they fall into a relevant cluster without
mutations in TERT, ATRX or DAXX and have no ALT phenotype.
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Figure 5.8: Properties of telomeres across different tumor clusters. (A) Distribution of
telomere sequence and properties across samples in the four clusters, with both tumour (blue
points) and matched normal (red points) shown. (B) Enrichment (positive T statistics) or deple-
tion (negative T statistics) of different variant sequence motifs in the four clusters of telomere
properties. (C) Variance of frequency of different sequence motifs across the four clusters.
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Figure 5.9: Properties of telomeres across different normal clusters. Properties of telomeres
across different normal clusters. Enrichment (positive T statistics) or depletion (negative T
statistics) of different variant sequence motifs in the four normal clusters of telomere properties.
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Figure 5.10: Co-mutation and expression levels of genes related to telomere maintenance
across the four clusters of telomere properties. (A) Patterns of co-mutation of the rele-
vant driver mutations across individual patients. Columns in plot represent individual patients,
coloured by type of abnormality observed. (B) Box and whisker plots of expression levels of
key telomere maintenance genes across the four clusters of telomere properties. The boxes
demarcate the interquartile range, with a horizontal line to mark the median.
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This route gives subtly different properties of telomeric sequence compared to tumours with
ALT through inactivated DAXX, which fall almost exclusively in cluster C2. The finding of a
distinct cluster of telomeric features, C3, so strongly associated with thyroid adenocarcinomas
remains unexplained.
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Figure 5.11: Timing of mutation in genes related to telomere maintenance. Clonal [early]
denotes clonal mutations occurring before duplications involving the relevant chromosome (in-
cluding whole genome duplications); clonal [late] to clonal mutations occurring after such du-
plications; and clonal [NA] to mutations occurring when no duplication was observed.
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Chapter 6
Future Directions and Conclusion
6.1 Future Directions
Despite the efforts of TCGA and ICGC, there is still a lack of data for the majority
of tumor types, including rare adult and pediatric tumors. For example, in the TCGA data,
BRCA-type cancers have over 1,000 samples while UVM-type cancers have only about 80
samples. This is just one example of the many underrepresented tumor types among the TCGA
and ICGC data.[63]. Of course, BRCA is a relatively common cancer mutation so there is
an abundance of individuals to pull samples from, but there remains an immediate need for
a greater variety of sample data to better understand and improve cancer treatments. LURE
requires a minimum of 3-4 samples with a specific unclassified mutation in order to associate
an event with a known driver, so tumor types with a lower number of samples are incompatible
with LURE. In addition, it is difficult to draw statistical power with such a small number of
samples. The PCAWG analysis put forth great effort to find driver mutations in the non-coding
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regions of the genome, but they only sequenced approximately 2,500 tumor samples and about
half of these samples were not analyzed for gene expression data. Some specific tumor types had
fewer than 10 samples. As I learned from the fusion detection method challenge, sequencing
coverage was vital in accurate fusion detection. Thus, in addition to more sample types, we
need samples with higher coverage to accurately make confident mutation calls.
Improving cancer detection technologies is an important goal of cancer genomics re-
search, as early detection of cancer improves patient response to treatment and overall prognosis[64].
One particular method of early detection involves analyzing cell free DNA (cfDNA) in blood
plasma for specific biomarkers to reveal the existence of a tumor in the body. cfDNA contains
both tumor-derived DNA, or ”circulating tumor DNA” (ctDNA), and DNA derived from non-
tumor cells such as hematopoietic and stromal cells[65]. ctDNA shares unique characteristics
of tumor DNA, such as cancer-associated mutations, translocations, and/or large CNVs not typ-
ically found in the cfDNA of healthy patients[66]. In patients with cancer, ctDNA generally
represents a small fraction of the cfDNA, ranging from 5-10% in late-stage disease to 0.01-
1.0% in early-stage disease. This value is even lower in premalignant conditions, so methods
that consider both ctDNA and total cfDNA could be very beneficial[67]. The goal of an early
cancer detection method would be to identify the existence of a tumor as well as the tumor’s
subtype. Recently, a method was published that uses machine learning to predict the existence
of colon cancer among 546 patients and 271 non-cancer control subjects using a supervised ma-
chine learning[65]. The cancer patients were divided equally by gender and consisted of 80&
early-stage (stages I and II) patients[65]. The cfDNA of the 817 total subjects was sequenced
using whole genome sequencing and their machine learning method was able to correctly di-
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agnosis the cancer patients with a mean ROC AUC of 0.92[65]. To date, this was the largest
study using only cfDNA whole genome sequencing in patients for the early detection of colon
cancer. While the group was successfully able to build a classification model to determine the
existence of a tumor, an analysis of feature importance was absent. Such feature importance
analysis could possibly reveal novel biomarkers, which would limit the amount of sequencing
necessary to make a prediction and allow hospitals to perform early tumor detection without
invasive procedures.
6.2 Conclusion
It is widely accepted that tumorigenesis is a multistep process that depends on the
sequential accumulation of mutations within cells[68]. Although tumor cells often exhibit
a large number of mutations[69][70], only a relatively small subset is crucial for neoplastic
development[70][71][72]. In this thesis, I presented multiple methods and the necessary data to
categorize and prioritize mutations as potential drivers for tumorigenesis using both supervised
and unsupervised machine learning. In chapter one, I showed that low sequencing coverage
is the most important feature that causes fusion detection methods to fail in identifying fusion
breakpoints. By increasing sequencing coverage, we can identify more fusions and potentially
identify more cancer drivers in samples that have no known drivers. In chapter two, I presented
a new method called LURE, which associates different alterations based on mRNA expression
signatures using supervised machine learning. I identified associations between alterations in
the same gene, the same gene family, and within the same pathway. Using LURE I also found
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new associations in Sarcomas, linking ATRX mutations with two new possible drivers of the
ALT TMM, RB1 and SP100. In order to provide an orthogonal analysis supporting these re-
sults, I present unsupervised clustering of TMM features in Chapter three. This revealed a sub-
group of samples harboring mutations in RB1 and showing characteristics of ALT. In addition,
I presented results from a network and pathway analysis showing how non-coding mutations
in splicing factors can affect tumors in the same manner as a coding mutation in the splicing
factor. In this thesis, I presented just a glimpse of the on-going research in the field of cancer
genomics. I hope to inspire new ideas and spur greater interest in the field of genomics with the
intention of overcoming the extremely convoluted problems associated with cancer.
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